Q4 2024 Harrow Inc Earnings Call Transcript
Key Points
- Harrow Inc (HROW) reported a record financial performance for 2024, with a 53% increase in full-year revenues to $199.6 million.
- The company achieved a remarkable 84% increase in fourth-quarter revenue compared to the same period in 2023.
- Adjusted EBITDA for 2024 increased by 43% to $40.3 million, indicating strong operational efficiency.
- The launch of the VEVYE Access for All program is expected to boost prescription volumes and support consistent revenue growth.
- Harrow Inc (HROW) has secured CMS approval for TRIESENCE reimbursement, positioning it for significant revenue contributions starting in Q2 2025.
- The company experienced delays in filing its Form 10-K due to a merger with a new auditing firm, which they aim to avoid in the future.
- Despite strong performance, Harrow Inc (HROW) acknowledges potential quarter-to-quarter volatility in unit demand for its products.
- The company plans to stop reporting prescription data to IQVIA, which may lead to less accurate and actionable data for stockholders.
- There is a risk associated with the extended payment terms offered to distributors, impacting cash flow in Q4 2024.
- Harrow Inc (HROW) anticipates starting to pay taxes in 2025, which will impact cash flow conversion from adjusted EBITDA.
Good morning, and welcome to Harrow's fourth quarter and year end 2024 earnings conference call. My name is Gigi, and I'll be your operator for today's call. At this time, all participants are in a listen only mode. Later, we will conduct a question-and-answer session. As a reminder, this conference is being recorded.
I would now like to turn the call over to Jamie Webb, Director of Communications and IR for Harrow.
Thank you, operator. Good morning, and welcome to Harrow's fourth quarter and year end 2024 earnings conference call. Before we begin today, let me remind you that the company's remarks may include forward-looking statements within the meaning of federal securities laws. F
orward-looking statements are subject to numerous risks and uncertainties, many of which are beyond Harrow's control, including risks and uncertainties described from time to time in its SEC filings, such as the risk and uncertainties related to the company's ability to make commercially available its
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
